HOOK240719C7500
- 0.05
- 0.000.00%
HOOKIPA Pharma Newsroom
HOOKIPA Pharma Doses First Patient In Phase 1b Trial Of HIV Therapeutic Vaccine
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study
HOOKIPA Pharma (HOOK) said Monday the first person has been dosed in its phase 1b study of its investigational vaccine HB-500 for the treatment of HIV. The study will evaluate safety and tolerability,
Express News | HOOKIPA Pharma Inc - Under Collaboration Agreement, HOOKIPA Is Responsible for Advancing Hiv Program Through Completion of a Phase 1B Clinical Trial
Express News | HOOKIPA Pharma Inc - HOOKIPA Achieves a $5 Mln Non-Dilutive Milestone Payment Under Its Collaboration and License Agreement With Gilead
Express News | HOOKIPA Pharma Announces First Person Dosed in Phase 1B Clinical Trial of Hb-500 for the Treatment of Hiv
Investors Don't See Light At End Of HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Tunnel And Push Stock Down 25%
HOOKIPA Pharma Inc. (NASDAQ:HOOK) shares have had a horrible month, losing 25% after a relatively good period beforehand. Instead of being rewarded, shareholders who have already held through the l
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Keybanc rai
HOOKIPA Pharma Is Maintained at Buy by HC Wainwright & Co.
HOOKIPA Pharma Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co.: Maintains a buy rating on hookipa pharma (HOOK.US), adjusted from buy to buy rating, with a target price of $6.00, adjusted from $5.00.
HOOKIPA Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/05/2024 640.74% HC Wainwright & Co. $5 → $6 Maintains Buy 05/21/2024 517.28% RBC Capital $5 → $5 Reiter
H.C. Wainwright Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Raises Target Price to $6
H.C. Wainwright analyst Arthur He CFA maintains $HOOKIPA Pharma(HOOK.US)$ with a buy rating, and adjusts the target price from $5 to $6.According to TipRanks data, the analyst has a success rate of 53
Express News | HOOKIPA Pharma Inc. : H.c. Wainwright Raises Target Price to $6 From $5
HOOKIPA Pharma Announces Phase 2 Results For HB-200 Combined With Pembrolizumab In HPV16+ Head And Neck Cancer
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-
Express News | Hookipa Pharma announced updated phase 2 clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2024 in the USA.
Express News | HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20Conference call on Tuesday, June 4, at 4:15 p.m. ET NEW YORK and VIENNA,
12 Health Care Stocks Moving In Monday's Intraday Session
GainersInnovative Eyewear (NASDAQ:LUCY) shares moved upwards by 421.5% to $0.97 during Monday's regular session. The company's market cap stands at $16.9 million. OneMedNet (NASDAQ:ONMD) shares moved
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Maintains Target Price $5
JMP Securities analyst Roy Buchanan maintains $HOOKIPA Pharma(HOOK.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 32.2% and
Buy Rating Affirmed for Hookipa Pharma Amid Positive HB-200 Vaccine Trials and Robust Financial Position
HOOKIPA Stock Falls 20% in Wake of Phase 1/2 Study Results